Scarborough, Canada Clinical Trials

A listing of Scarborough, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy.

cancer
durvalumab
systemic therapy
sorafenib
liver cancer
Research Site
 (8.1 away) Contact site
  • 273 views
  • 02 Sep, 2021
  • +247 other locations
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming …

mastectomy
invasive carcinoma
tamoxifen
core needle biopsy
breast-conserving surgery
Odette Cancer Centre- Sunnybrook Health Sciences Centre
 (8.1 away) Contact site
  • 598 views
  • 15 Sep, 2021
  • +318 other locations
Using Big Data to Conduct Innovative Cardiovascular Clinical Trials

Traditional randomized clinical trials (RCTs) have provided extremely valuable information on medical therapies and procedures that have changed the way heart diseases are treated. However, despite these contributions, traditional RCTs are costly, the findings may not be applicable to patients unlike those in the study, and the use of trial …

statin
hmg-coa reductase inhibitors
cholesterol level
hmg-coa reductase inhibitor
stroke
ICES
 (8.1 away) Contact site
  • 3 views
  • 03 Sep, 2021
  • 1 location
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

The study is a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with nAMD (neovascular age related macular degeneration) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment. Patients who consent will undergo screening assessments to evaluate their eligibility based on the inclusion and exclusion criteria.

aflibercept
retinopathy
vegf
vascular endothelial growth factor
macular degeneration
Novartis Investigative Site
 (8.1 away) Contact site
  • 30 views
  • 15 Sep, 2021
  • +135 other locations
A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival

The main objective of this study is to evaluate safety and efficacy of venetoclax in combination with azacitidine (AZA) and best supportive care (BSC) compared to BSC as maintenance therapy in adult participants with acute myeloid leukemia (AML) in first remission after conventional chemotherapy. This study will be conducted in …

cancer
venetoclax
consolidation chemotherapies
azacitidine
remission
Sunnybrook Health Sciences Ctr /ID# 215681
 (8.1 away) Contact site
  • 40 views
  • 15 Sep, 2021
  • +306 other locations
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is …

solid tumour
kinase inhibitor
clear cell renal cell carcinoma
tyrosine
vegf
Sunnybrook Research Institute ( Site 0153)
 (8.1 away) Contact site
  • 168 views
  • 15 Sep, 2021
  • +182 other locations
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the …

Sunnybrook Health Sciences Centre
 (8.1 away) Contact site
  • 7 views
  • 15 Sep, 2021
  • +38 other locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

anticoagulation therapy
vitamin k
aspirin
ticagrelor
fibrillation
Sunnybrook Hospital
 (8.1 away) Contact site
  • 112 views
  • 15 Sep, 2021
  • +79 other locations
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FR. Patients will be, in the opinion of the Investigator, appropriate …

doxorubicin
immunological adjuvant
mirvetuximab soravtansine
immunostimulant
cancer of the ovary
Sunnybrook Health Sciences Center
 (8.1 away) Contact site
  • 88 views
  • 10 Sep, 2021
  • +156 other locations
Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Novartis Investigative Site
 (8.1 away) Contact site
  • 143 views
  • 15 Sep, 2021
  • +558 other locations